gvtcx

Medical genetic testing kits

Cardiff and Vale University Health Board Published 28 May 2026 Find a Tender

key details

Statuscomplete
RegionWales
Proceduredirect
OCIDocds-h6vhtk-05a434

Award

SupplierValueDateStatus
MRC Holland £96,000 · active

description

The All Wales Medical Genomics Service (AWMGS) has routinely utilised Multiplex Ligation-Dependent Probe Amplification (MLPA) as a diagnostic tool for identifying Copy Number Variations (CNVs)—including deletions and duplications—across a range of genetic disorders. This testing supports clinical decision-making and patient treatment strategies.MLPA technology involves the use of oligonucleotide probe pairs that hybridise to specific DNA sequences within target genes. When both probes bind adjacently at a site of interest, they are ligated and subsequently amplified via Polymerase Chain Reaction (PCR). The amplified DNA fragments are then separated by capillary electrophoresis and analysed to detect CNVs.Since its inception, AWMGS has exclusively sourced MLPA probes and reagents from MRC Holland, a Netherlands-based supplier recognised for its specialised products in molecular diagnostics.

notice history

2 notices published against this procurement.

PublishedTypeRegimeNotice
29 Sept 2025 Transparency notice (UK5) Procurement Act 2023 060578-2025
28 May 2026 Contract details (UK7) Procurement Act 2023 050045-2026

more from Cardiff and Vale University Health Board

all contracts from this buyer →

source

Published on Find a Tender. Contact details for named individuals are not reproduced on this site.